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Background: Plasma calprotectin is a potential biomarker of cardiovascular disease (CVD), insulin resistance (IR), and
obesity. We examined the relationship between plasma calprotectin concentrations, CVD manifestations and the
metabolic syndrome (MetS) in patients with type 2 diabetes mellitus (T2DM) in order to evaluate plasma
calprotectin as a risk assessor of CVD in diabetic patients without known CVD.
Methods: An automated immunoassay for determination of plasma calprotectin was developed based on a fecal
Calprotectin ELIA, and a reference range was established from 120 healthy adults. Plasma calprotectin
concentrations were measured in 305 T2DM patients without known CVD. They were screened for carotid arterial
disease, peripheral arterial disease (PAD), and myocardial ischemia (MI) by means of carotid artery ultrasonography,
peripheral ankle and toe systolic blood pressure measurements, and myocardial perfusion scintigraphy.
Results: The reference population had a median plasma calprotectin concentration of 2437 ng/mL (2.5-97.5%
reference range: 1040–4262 ng/mL). The T2DM patients had significantly higher concentrations (3754 ng/mL,
p < 0.0001), and within this group plasma calprotectin was significantly higher in patients with MetS (p < 0.0001) and
also in patients with autonomic neuropathy, PAD, and MI compared with patients without (p < 0.001, p = 0.021 and
p = 0.043, respectively). Plasma calprotectin was by linear regression analysis found independently associated with BMI,
C-reactive protein, and HDL cholesterol. However, plasma calprotectin did not predict autonomic neuropathy, PAD, MI
or CVD when these variables entered the multivariable regression analysis as separate outcome variables.
Conclusion: T2DM patients had higher concentrations of plasma calprotectin, which were associated with obesity, MetS
status, autonomic neuropathy, PAD, and MI. However, plasma calprotectin was not an independent predictor of CVD, MI,
autonomic neuropathy or PAD.
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The inflammatory myeloid-related protein complex cal-
protectin, also known as MRP8/14, is a heterodimer
comprised of two intracellular calcium-binding proteins,
S100A8 (MRP8) and S100A9 (MRP14), predominantly
expressed in activated human neutrophils, monocytes and
macrophages. Calprotectin is actively secreted during the
stress response of phagocytes [1] and was found to be as-
sociated with inflammation more than 20 years ago [2].
Recently, calprotectin was identified as an endogenous ac-
tivator of Toll-like receptor 4 and as receptor for advanced
glycation end products (RAGE) [3] and calprotectin is
believed to function both as an intracellular differentiation
marker for phagocytes and as an extracellular protein
complex (a damage-associated molecular pattern (DAMP)
molecule) [4]. Elevated plasma levels of calprotectin have
been reported in a variety of chronic inflammatory condi-
tions, including rheumatoid arthritis, allograft rejection, in-
flammatory bowel disease, cancer and lung diseases [5].
In vivo studies in mice have shown that calprotectin pro-
mote atherosclerosis [6]. Furthermore, elevated calprotec-
tin levels have been reported to predict microvascular
alterations in type 2 diabetes (T2DM) patients [7] and was
found to be an early and sensitive marker of acute coron-
ary syndrome [8] and nonfatal myocardial infarction [9].
In a screening approach among healthy individuals, in-
creased plasma concentrations of calprotectin were found
to predict the risk of future cardiovascular events [10].
Furthermore, levels of plasma calprotectin appear to in-
crease earlier than other markers of myocardial necrosis
(myoglobin, creatine kinase–MB, and troponin), and high
levels are associated with an increased risk of recurrent
cardiovascular events [9].
T2DM is a disease characterized by increasing insulin re-
sistance over time and is commonly associated with hyper-
tension, hyperlipidemia, and obesity. These patients often
has a number of discrete CVD risk factors that together
with insulin resistance is known as the ‘metabolic syndrome’
as defined by the World Health Organization and the NCEP
Adult Treatment Panel III [11]. The major death cause in
T2DM patients is cardiovascular disease (CVD) [12].
Early identification and characterization of the risk of a
cardiovascular event in T2DM patients is therefore im-
portant in order to prevent these events. The identification
of a biomarker that can predict CVD would therefore be
useful in routine clinical use. The aim of the present study
was to investigate the association of plasma calprotectin
levels with CVD and other complications associated with
T2DM in a well-characterized T2DM cohort.
Methods
Control cohort for establishment of a reference range
Serum samples were obtained from a cohort of 120 adult
Danish blood donors in August and September 2011 atOdense University Hospital. All 120 individuals were
healthy and fulfilled the general demands for blood dona-
tion. Serum samples were obtained from 62 females and
58 males with an age ranging from 19 to 66 years. They
were stratified into subgroups by gender and age (<40 years
and ≥40 years). Informed consent was obtained prior to
donation of blood and the study was performed according
to the Declaration of Helsinki. All samples were aliquoted
and stored at −80°C until analysis.
Patient cohort
We consecutively evaluated 753 T2DM patients referred
to the Diabetes Clinic at Odense University Hospital,
Denmark, from January 2006 to December 2007 of
which 305 patients met the inclusion criteria as previ-
ously reported [13]. Briefly, the inclusion criteria were
(1) age >20 years, and (2) fasting C-peptide >250 pmol/L,
while the exclusion criteria were (1) any medical history
of CVD (stroke, myocardial infarction, coronary or pe-
ripheral revascularization, or ankle/toe systolic blood
pressure <50/30 mmHg), (2) suspected short lifespan due
to malignant disease and/or end-stage kidney disease, (3)
pregnancy or planned pregnancy during the study period,
(4) body weight >150 kg, or (5) physical or mental disabil-
ity not enabling participation in the study.
The T2DM diagnosis was made according to the WHO
criteria [14]. Patients were screened for CVD by physical
examination, B-mode ultrasound scans of the carotid ar-
teries, ankle and toe systolic blood pressure measurements
and myocardial perfusion scintigraphy (MPS) as previ-
ously reported [13]. From the MPS images a summed
stress score (SSS) was calculated. The blood samples col-
lected from the T2DM patients were EDTA-plasma;
all samples were centrifuged, plasma was aliquoted and
stored at −80°C until analysis. The study was carried
out according to Good Clinical Practice, followed the
Helsinki II Declaration, was approved by the Local Ethics
Committee (De Videnskabsetiske Komitéer for Region
Syddanmark), and is registered at http://www.clinicaltrials.
gov (Identification-nr: NCT00298844). All participants
gave written, informed consent.
Definition of obesity, insulin resistance and metabolic
syndrome
Overweight and obesity were defined as a body mass index
(BMI) 25–30 kg/m2 and > 30 kg/m2, respectively, as pro-
posed by WHO. Insulin resistance (IR) was calculated using
a homeostasis model assessment (HOMA) of IR (HOMA-
IR = fasting glucose (mmol/L) × fasting insulin (μU/mL)/
22.5) [15]. The presence of the metabolic syndrome was
assessed according to the American Heart Association
guidelines, defined as waist circumference ≥102 cm in men
and ≥88 cm in women, triglycerides ≥1.69 mmol/L, HDL-
Cholesterol <1.03 mmol/L in men and <1.29 mmol/L in
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plasma glucose ≥5.6 mmol/L [16].
Laboratory analyses
Calprotectin measurement
Analysis of serum/plasma calprotectin was performed
with a new fully automated Fluorescent Enzyme Sandwich
Immuno Assay designed for measurement of fecal Calpro-
tectin (ELIA Calprotectin for ImmunoCap250, 250-5611-
01/UK). The ELIA calprotectin assay uses recombinant
human calprotectin as standard and the wells are coated
with monoclonal antibodies directed towards calprotectin.
After incubation with the sample the wells were washed to
remove non-bound calprotectin, and enzyme-labeled anti-
bodies against human calprotectin were added to form a
calprotectin-conjugate complex. After incubation an add-
itional wash was performed in order to remove non-
bound conjugate and finally, development solution was
added. After terminating the reaction fluorescence was
measured directly using an ImmunoCap250 (Thermo
Scientific Life Technologies, Waltham, MA, USA). Data
from all measurements were plotted as a four-parameter
logistic (4PL) curve fit of the fluorescent counts versus
standard concentrations using GraphPad Prism software
(version 5; GraphPad Software, La Jolla, CA) from which
the concentrations of plasma calprotectin were calculated.
The ELIA Fecal Calprotectin assay was validated for use
on plasma/serum samples. Prior to analysis, serum/plasma
samples were diluted 1:100 in ELIA Sample Diluent. The
linear range was determined using a sample with a calpro-
tectin concentration of 14700 ng/mL, which was serially
diluted to create ten samples that were tested in duplicate.
The results were linear over a concentration range of 2.3-
14700 ng/mL (y = 1.08× + 0.12, R2 = 0.997). The quantifica-
tion limit of the assay was 3.0 ng/mL defined as the value
10 standard deviations (SD) above the mean value of the
zero standard (n = 7). Within-run imprecision was 4.5%
and between-run imprecision was 5.6% for a serum pool
with a mean calprotectin concentration of 5234 ng/mL.
Since the available test material were limited to serum
from the control cohort and plasma from the patient co-
hort, a comparison of the calprotectin levels in serum and
plasma was performed:Calprotectin was measured in 58
matching plasma and serum samples, which showed a
significant correlation between the two sample types
(Spearman’s correlation coefficient; r = 0.899, p < 0.001)
and with no statistical significant differences in the median
values for the two sample types when compared by
Mann–Whitney U-test (p = 0.191).
Other biochemical measurements
HbA1c (glycated hemoglobin) was measured by cation-
exchange chromatography using Tosoh G7 (Medinor,
Broendby, Denmark) with dedicated reagents. Glucose,total cholesterol, LDL cholesterol, HDL cholesterol, and
high-sensitive CRP (hs-CRP) were all analyzed on a Modu-
lar Analytics P (Roche Diagnostics, Switzerland) with the
methods applied as recommended by the supplier.
Statistical analyses
Continuous variables are presented as mean and stand-
ard deviations, categorical variables as numbers and
percentages with 95% confidence intervals (CI). Student’s
t-test was used to test differences between independent
continuous variables. Due to a non-Gaussian distribution
of hs-CRP, HOMA-IR and plasma calprotectin, these pa-
rameters are presented as median and interquartile
range, and the Mann–Whitney test was used to compare
groups. For comparison of categorical variables with
more than two groups, a Kruskall-Wallis nonparametric
test was used. Due to the non-Gaussian distribution, bi-
variate Spearman correlation coefficients were used to
describe the association between plasma calprotectin
levels and other continuous variables. Multiple stepwise
regression analysis was performed with plasma calpro-
tectin concentrations as dependent variable and by en-
tering independent variables with the highest partial
correlation coefficient at each step with an F-value prob-
ability for inclusion of 0.05 and 0.01 for removal.
Logistic regression analysis was performed using auto-
nomic neuropathy, PAD and MI as separate outcome
variables. The co-variables were adjusted for age, CRP
and BMI. Results are reported as odds ratio (OR) with
95% CI and p-values. A p-value < 0.05 was considered
statistically significant. SPSS for Windows version 20
(SPSS Inc., Chicago, Illinois) was used for calculations.
Results
Establishment of a reference range
The one-sample Shapiro-Wilk test of normality showed
that the distribution of serum calprotectin was non-
Gaussian (Z = 0.114, p = 0.001) and positively skewed
(skewness = 1.256). Therefore, construction of the refer-
ence range employed a non-parametric approach. The
median calprotectin concentration was 2437 ng/mL with
the reference range determined as 1040–4262 ng/mL
(2.5th-97.5th percentile). No significant difference be-
tween the genders were found (Mann–Whitney U-test;
p = 0.805).
Baseline characteristics and plasma calprotectin
concentrations in the type 2 diabetes cohort
Baseline clinical and metabolic characteristics and the
prevalence of CVD in the 305 T2DM patients have pre-
viously been reported [13,17]. Added information from
this study concerning prevalence of MetS, HOMA-
IR and calprotectin concentrations are presented in
Table 1.
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5.8 kg/m2 (mean ± SD) and 243 of the 305 patients had
metabolic syndrome according to the criteria of the
American Heart Association. Median plasma calprotec-
tin concentration was 3754 (2288–5797) ng/mL (median
(IQR)), which was significantly higher than in the healthy
reference population (Mann–Whitney U-test; p < 0.001).
The median HOMA-IR was significantly higher in
T2DM patients with CVD compared to those without
(4.4 (2.5-8.3) vs. 3.4 (2.1-5.5), p = 0.004), but patients
with and without CVD did not differ in median plasma
calprotectin concentrations (3754 (2290–6194) ng/mL
vs. 3753 (2278–5170) ng/mL; median (IQR), p = 0.39).
However, the median plasma calprotectin concentration
was significantly higher in subjects with metabolic syn-
drome compared with subjects without (3916 (2468–
6245) vs. 2943 (1793–4115) ng/mL), p < 0.0001).Correlation of plasma calprotectin with clinical,
anthropometric and biochemical parameters
Partial Spearman correlation analysis of data from all
305 T2DM patients showed that plasma calprotectin
levels were highly correlated with BMI, weight, waist cir-
cumference, hip circumference, age (inversely), hs-CRP,
fasting plasma insulin, plasma HDL (inversely), HOMA-
IR and Summed Stress Score (SSS) (all p < 0.001), while
weakly correlated with fasting plasma C-peptide, dia-
betes duration (inversely), carotid intima media thick-
ness (CIMT) (inversely) and triglycerides (all p < 0.05).
Partial Spearman correlation analysis was also performed
in T2DM patients with and without metabolic syn-
drome, respectively. Data are presented in Table 2.
All parameters significantly correlated with plasma cal-
protectin in the 305 T2DM patients entered a stepwise
multiple regression analysis. The independent predictors
of plasma calprotectin concentrations obtained from this
analysis are presented in Table 3; the ANOVA inflation
factors excluded multicollinearity for these variables.
When stratifying by quartiles of calprotectin con-
centrations, the variables BMI, fasting C-peptide, fasting
insulin, HOMA-IR and hs-CRP increased significantly
across calprotectin quartiles (all p < 0.05, ANOVA),
while HDL cholesterol concentrations decreased signifi-
cantly across calprotectin quartiles (p < 0.001, ANOVA)
(Figure 1).Table 1 Data are median (interquartile range) or n (%)
Total (n = 305) C
Metabolic syndrome/no metabolic syndrome 243/62 1
Calprotectin (ng/mL) 3754 (2288–5797) 3
HOMA-IR 3.9 (2.3-7.4) 4
Data are median (interquartile range) or n (%). CVD by examination = cardiovascula
and toe systolic blood pressure measurements and/or myocardial perfusion scintigrAssociations of calprotectin with cardiovascular disease
manifestations in T2DM
Association of calprotectin concentrations with CVD man-
ifestations is presented in Figure 2. Median plasma calpro-
tectin concentrations did not differ between patients with
and without CVD manifestations (p = 0.39), but were sig-
nificantly higher in patients with PAD compared to pa-
tients without (4800 (900–11700) vs. 3600 (1000–12800)
ng/mL, p = 0.021). There were statistical significantly
higher levels of calprotectin in autonomic neuropathy com-
pared to no autonomic neuropathy (4820 (1414–13958) vs.
3565 (902–10811) ng/mL, p < 0.001). For MI, plasma cal-
protectin concentrations only just reached significance
higher values compared to patients without MI (4003
(1019–13187) vs. 3678 (955–12745) ng/mL, p = 0.043).
Plasma calprotectin was also associated with autonomic
neuropathy and with myocardial ischemia (Figure 2).
To further test the association of plasma calprotectin
concentrations with disease manifestations a multivariate
logistic regression analysis were performed with auto-
nomic neuropathy, PAD and MI, as separate outcome var-
iables. In this analysis plasma calprotectin did not show
any significant association with autonomic neuropathy
(adjusted OR 1.00; 95% CI: 0.958-1.045, p = 0.991), PAD
(adjusted OR: 1.00; 95% CI: 1.00-1.00, p = 0.052), MI (ad-
justed OR: 1.00; 95% CI: 1.00-1.00, p = 0.413) nor CVD
(adjusted OR: 1.00; 95% CI: 1.00-1.00, p = 0.857).
Discussion
The major findings in our present study were (1) higher
levels of plasma calprotectin in T2DM patients com-
pared with a general population, (2) plasma calprotectin
levels correlated with BMI, triglyceride, HDL cholesterol
(inversely), hs-CRP, insulin and C-peptide levels as well
as HOMA-IR in T2DM patients, (3) plasma calprotectin
was independently associated with BMI, hs-CRP and
HDL cholesterol (inversely), (4) higher levels of plasma
calprotectin were found in patients with MetS compared
to patients without, and (5) the plasma level of calpro-
tectin was not associated with CVD in T2DM patients
but higher levels of plasma calprotectin were found in
patients with autonomic neuropathy, PAD and myocar-
dial ischemia compared with patients without. Of note,
plasma calprotectin could not predict autonomic neur-
opathy, PAD, myocardial ischemia or CVD in T2DM pa-
tients in a multivariate logistic regression analysis.VD by examination (n = 183) No CVD by examination (n = 122)
54/29 91/31
754 (2290–6194) 3753 (2278–5170)
.4 (2.5-8.2) 3.4 (2.1-5.0)
r disease obtained from B-mode ultrasound scans of the carotid arteries, ankle
aphy.
Table 2 Bivariate Spearman correlation between calprotectin and other biochemical markers and metabolic features in
patients with and without metabolic syndrome
Metabolic syndrome (n = 243) No metabolic syndrome (n = 62)
ρ P ρ P
Age (years) −0.179 0.005 −0.138 0.294
Weight (kg) 0.199 0.002 0.317 0.014
Height (m) −0.129 0.046 −0.211 0.106
BMI (kg/m2) 0.252 <0.001 0.446 <0.001
Waist circumference (cm) 0.237 0.001 0.257 0.047
Hip circumference (cm) 0.230 <0.001 0.285 0.027
Diabetes duration (years) −0.172 0.008 0.092 0.486
CIMT (mm) −0.114 0.079 −0.168 0.200
Fasting p-glucose (mmol/L) −0.148 0.021 −0.069 0.601
HbA1c (%) −0.037 0.564 −0.052 0.691
Fasting C-peptide (pmol/L) 0.081 0.212 0.177 0.176
Fasting insulin (pmol/L) 0.169 0.009 0.247 0.057
Total cholesterol conc. (mmol/L) −0.072 0.268 0.084 0.523
LDL-cholesterol conc. (mmol/L) 0.002 0.978 0.131 0.318
HDL-cholesterol conc. (mmol/L) −0.151 0.019 −0.259 0.045
Triglycerides (mmol/L) 0.018 0.779 0.289 0.025
Creatinine (μmol/L) 0.000 0.995 0.022 0.868
hs-CRP (mg/L) 0.415 <0.001 0.346 0.007
HOMA-IR 0.110 0.088 0.169 0.197
SSS 0.136 0.035 0.222 0.088
Statistical significant results are shown in bold.
Table 3 Overall multiple regression analysis between
plasma calprotectin levels (dependent variable) and the
variables significantly correlated to this parameter in all
subjects
Independent variable All cases (n = 305)
Model I β P
Age (years) −0.039 0.516
Weight (kg) −0.249 0.016
BMI (kg/m2) 0.228 <0.001
Waist circumference (cm) −0.087 0.357
Hip circumference (cm) 0.058 0.588
Diabetes duration (years) −0.086 0.120
CIMT (mm) −0.073 0.189
Fasting C-peptide (pmol/L) 0.030 0.617
Fasting insulin (pmol/L) 0.053 0.378
HDL-cholesterol conc. (mmol/L) −0.153 0.005
Triglycerides (mmol/L) −0.040 0.501
HOMA-IR −0.004 0.943
SSS 0.015 0.788
hs-CRP (mg/L) 0.235 <0.001
Statistical significant results are shown in bold. Model summary: R = 0.408.
Predictors; BMI, p = 0.001, hs-CRP, p < 0.001 and HDL, p = 0.005.
Figure 1 Relative increase/decrease of BMI, fasting C-peptide,
fasting insulin, HDL cholesterol, HOMA-IR and hs-CRP across
calprotectin quartiles. The difference across quartiles were
significant at the p < 0.0001 (ANOVA) level for BMI and hs-CRP and
at the p < 0.05 level (ANOVA) for fasting C-peptide, fasting insulin,
HDL and HOMA-IR (ANOVA).
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Figure 2 Plasma calprotectin levels in patients without (1) or with
PAD (2), without (3) or with autonomic neuropathy (4) and without
(5) or with MI (6). P-values are from a Mann–Whitney U-test.
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possible clinical relevance.
The finding of higher plasma calprotectin levels in
T2DM patients compared to a reference population is
likely to reflect that calprotectin is released by macro-
phages and therefore are involved in systemic inflamma-
tory diseases such as juvenile idiopathic arthritis [18] or
sepsis [19]. T2DM is often characterized as a state of
chronic, low-grade inflammation that contributes to insu-
lin resistance and is associated with prolonged obesity and
dyslipidemia [20]. Adipose tissue macrophage infiltration
increases in mice and humans as they become obese [21]
and abnormal fat accumulation is associated with in-
flammatory changes, including recruitment of macro-
phages and activation of endothelial cells [22]. High levels
of plasma calprotectin have previously been shown to cor-
relate with obesity in humans [19,23,24] and it is plausible
that the higher levels of plasma calprotectin in obesity is
caused by the adipose tissue macrophages and that the
obesity-induced inflammation is mediated by the calpro-
tectin/TLR-4/inflammation pathway leading to a systemic-
ally rise in plasma levels. Recently, MRP8 mRNA was
found over-expressed in mouse white adipose tissue and
3 T3-L1 adipocytes suggesting that inflamed adipose tissue
might be a major source of the calprotectin found in
plasma [25]. In vitro studies by Catalan and co-workers
showed a higher MRP8 mRNA expression levels in the
stromovascular fraction cells in visceral adipose tissue
(VAT) and they suggest a potential role of calprotectin as
a chemotactic factor in the recruitment of macrophages to
VAT, increasing inflammation and the development of
obesity-associated co-morbidities [25]. That the expression
level of MRP8 in human adipocyte culture increases upon
stimulation with the cytokine TNF-alpha suggests a causa-
tive link [23].So far, few studies have addressed the relationship
between circulating levels of calprotectin, glucose homeo-
stasis and insulin resistance. Our data indicate that the ele-
vated levels of calprotectin in T2DM patients are linked to
obesity independent of dysglycemia and insulin resistance.
Mortensen and co-workers likewise found no significant
association between circulating calprotectin and parame-
ters of glucose homeostasis [24], which was also observed
in a Chinese study [26]. On the other hand, Ortega and
co-workers recently found plasma and urinary levels of
calprotectin associated with insulin resistance and low-
grade inflammation independent of obesity in T2DM pa-
tients, which lead to the hypothesis that calprotectin may
be a biomarker of decreased insulin sensitivity beyond a
common trait of obesity and inflammation [27]. The lack
of association between calprotectin levels and glucose
homeostasis in this study seems, however, to confirm that
the regulation of calprotectin is independent of glucose
metabolism.
Plasma calprotectin has previously been shown to be a
useful biomarker of CVD risk [8-10], but the pathophysio-
logical connection between higher plasma calprotectin
concentrations and CVD is not known. It is unclear
whether calprotectin is simply a marker of systemic low-
grade inflammation or plays a more specific role in the
processes that promotes atherosclerosis leading to CVD.
Over-expression of calprotectin in the infarcted myocar-
dium and higher levels of plasma calprotectin in patients
with acute myocardial infarction seems to support a direct
role of the protein complex in the pathophysiology of
acute myocardial infarction [28]. Supporting this are
studies that show an infiltration of monocytes expressing
calprotectin in atherosclerotic lesions [29] and a higher
expression of calprotectin in atherosclerotic lesions [6].
Also, calprotectin-deficient mice seem protected against
vascular injury and have smaller atherosclerotic lesions,
less plaque inflammation and decreased re-stenotic re-
sponse [6]. The usefulness of calprotectin as a CVD
predictor is, however, not straightforward: Peng and co-
workers reported that diabetic patients with coronary ar-
tery disease (CAD) had elevated plasma calprotectin
levels, and that the level of plasma calprotectin correlated
with the severity of CAD and CIMT in patients without
clinically overt CAD [26]. On the contrary, Bauman and
co-workers failed to detect any significant differences in
circulating calprotectin levels in patients with or without
stable CAD [30]. Although this study shows slightly higher
levels of plasma calprotectin in patients with MI, the lack
of association in our multivariate regression analysis and
the lack of consistency in cohort studies with CVD end
points still indicate that the use of calprotectin as a CVD
risk marker seems dubious.
In this study calprotectin correlated significantly with hs-
CRP levels and when included in our multiple regression
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sociated with the plasma calprotectin concentration sup-
porting a role of calprotectin as an obesity-associated
inflammation marker.
Although we not found an association of calprotectin
with CVD, measurement of plasma calprotectin could still
valuable when monitoring CVD or as a marker of therapy
response. A recent systematic review by Micha et al. ex-
amined CVD risk and the use of the anti-inflammatory
drug methotrexate and concluded that methotrexate use
was associated with a 21% lower risk of CVD and 18%
lower risk of myocardial infarction [31]. This lends prom-
ise to the notion that using markers of inflammation such
as calprotectin may allow for interventions to decrease
overall cardiovascular risk. Another well-known inflam-
mation marker is hs-CRP that in multiple prospective
studies has been shown to predict incident myocardial in-
farction, stroke, peripheral arterial disease, sudden cardiac
death and also adds prognostic information at all levels of
calculated Framingham Risk [32]. This indicates that valu-
able information could be retrieved using calprotectin as a
marker beyond what would be obtained with hs-CRP. The
availability of a fully automated plasma calprotectin assay
opens up for future studies that can evaluate whether cal-
protectin can be used in monitoring disease progression
and/or in intervention studies.
Conclusion
In conclusion, plasma calprotectin levels were associated
with the presence of MI, PAD and autonomic neuropathy
in a consecutive series of T2DM patients without known
CVD referred to a diabetes clinic for the first time. When
adjusting for hs-CRP, BMI and HDL cholesterol those as-
sociations, however, disappeared. Also, plasma calprotec-
tin was not a marker of insulin resistance independent of
inflammation and BMI. The finding of elevated plasma
calprotectin in subjects with MetS supports a role of cal-
protectin as a marker of obesity-associated chronic low-
grade inflammation.
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